Circumvent GTM brain

Circumvent develops investigational precision medicines for rare neurodegenerative diseases, initially CLN1 Batten disease.

category

Rare neurological disease therapeutics

market profile

  • text: CLN1 Batten disease is a rare, severe pediatric neurodegenerative disorder, creating a small and specialized treatment population.
  • text: Development includes IND-enabling work; an approved commercial product or current trial launch was not established.

personas

  • title: Pediatric neurologist at a rare disease center
    pains:
    • Few disease-modifying options for children with CLN1
    • Need for robust safety, efficacy and natural-history evidence before considering a new treatment
  • title: Batten disease patient advocacy leader or caregiver
    pains:
    • Rapid neurological decline and limited treatment options
    • Navigating trial information and communicating patient priorities to researchers
  • title: Pharma business development lead
    pains:
    • Finding differentiated rare neurological disease assets with a credible development path
    • Assessing translation and regulatory risk before partnership

icp

  • text: Specialist pediatric neurology and genetic disease centers treating or diagnosing Batten disease are potential future clinical stakeholders.
  • text: Rare disease pharmaceutical companies and research organizations with neurological development capabilities are plausible partners; partnership terms are not public.

message pillars

  • text: Focus on precision medicines in neurodegeneration.
  • text: Build on insights from Batten disease research.
  • text: Engage patients and caregivers to inform development.

objections

  • objection: Is the candidate proven in patients?
    response: The public evidence reviewed describes development work, not established clinical efficacy; request current trial and regulatory status.
  • objection: Can a CLN1 approach address other neurodegenerative diseases?
    response: The company is exploring broader biology, but evidence and clinical relevance must be assessed separately for each indication.

competitors

  • name: Taysha Gene Therapies
    why: Its CLN1 gene therapy program represents an alternative modality; its program was paused and license later terminated.
  • name: Collaborations Pharmaceuticals
    website: https://www.collaborationspharma.com/news/collaborations-pharmaceuticals-inc-and-collaborative-team-progress-development-of-a-treatment-for-batten-disease-cln1
    why: Developing an investigational enzyme replacement approach for CLN1.

influencers

  • name: Andrew Lim
    url: https://www.neurotechpartnering.com/18/Speaker-Bios
    why: Circumvent co-founder with a background in neurodegeneration therapeutics.

keywords

  • CLN1 Batten disease treatment
  • pediatric neurodegeneration drug development
  • protein palmitoylation therapeutic
  • rare neurological disease trial
  • Batten disease precision medicine

voice

  • Scientific
  • Patient-centered
  • Measured

signals

  • text: A center diagnoses or follows children with CLN1 and participates in natural history or clinical studies.
  • text: A pharma partner is seeking rare neurological assets and has clinical or regulatory development capacity.

pricing

model: unknown

motion

unknown

channels

  • Scientific research
  • Patient advocacy
  • LinkedIn

confidence

medium

Founders

  • name: Devin Wiley
    title: Founder
    role: Founder

Back to YC companies